UK markets closed

Idorsia Ltd (0RQE.IL)

IOB - IOB Delayed price. Currency in CHF
Add to watchlist
22.700.00 (0.00%)
At close: 6:29PM BST

Idorsia Ltd

Hegenheimermattweg 91
Allschwil 4123
Switzerland
41 58 844 00 00
http://www.idorsia.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees

Key executives

NameTitlePayExercisedYear born
Mr. Jean-Paul Clozel M.D.CEO & DirectorN/AN/A1955
Mr. André C. MullerExec. VP & CFON/AN/A1963
Dr. Martine ClozelExec. VP & Chief Scientific OfficerN/AN/A1955
Mr. Andrew C. WeissSr. VP and Head of Investor Relations & Corp. CommunicationsN/AN/A1968
Mr. Oliver PeineltSr. VP & Group Gen. CounselN/AN/A1970
Mr. Alexander KhatuntsevSr. VP & Head of HRN/AN/A1978
Dr. Guy BraunsteinExec. VP & Head of Global Clinical Devel.N/AN/A1956
Mr. Simon JoseExec. VP & Chief Commercial OfficerN/AN/AN/A
Mr. Olivier LambertSr. VP & Head of Pharmaceutical Devel.N/AN/A1966
Mr. Markus A. RiedererSr. VP & Head of Drug Discovery BiologyN/AN/A1962
Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CHF.

Description

Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; ReveraGen to research and co-develop vamorolone, a non-hormonal steroid modulator for the treatment of duchenne muscular dystrophy; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase 1 clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.

Corporate governance

Idorsia Ltd’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.